Search
for
Sort by
Research 331–360 of 1000+
- Cutaneous toxicities of cancer therapy
- Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
- Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
- Cutaneous Reactions to Chemotherapeutic Agents
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Skin toxicity of anti‐cancer therapy
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
- Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Topoisomerase‐Interacting Agents
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Comparative Outcomes of Cutaneous Vesicostomy Versus Cystoscopic Valve Ablation in the Initial Management of Posterior Urethral Valves
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
- Automated Machine Learning Analysis of Patients With Chronic Skin Disease Using a Medical Smartphone App: Retrospective Study